{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:23:41Z","timestamp":1774617821362,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-07916-2","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:35:39Z","timestamp":1771612539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of psychotropic medication use, medication switching, augmentation, and non-persistence in adolescents and young adults with co-occurring psychiatric morbidities and opioid use disorder"],"prefix":"10.1186","volume":"26","author":[{"given":"Ligang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin R.","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea E.","family":"Bonny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyndal","family":"Lemelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milap C.","family":"Nahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"7916_CR1","unstructured":"National Institutes of Health. The NIH HEAL Initiative: Understanding the opioid crisis. U.S. Department of Health and Human Services. Accessed August 6, 2025. https:\/\/heal.nih.gov\/about\/opioid-crisis"},{"issue":"5","key":"7916_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jadohealth.2024.12.015","volume":"76","author":"F Han","year":"2025","unstructured":"Han F, et al. Global, Regional, and National Epidemiology of Opioid Use Disorder Among Adolescents and Young Adults, 1990\u20132019. J Adolesc Health. 2025;76(5):905\u201313.","journal-title":"J Adolesc Health"},{"key":"7916_CR3","doi-asserted-by":"crossref","unstructured":"Liu L et al. Impact of Co-occurring psychiatric comorbidities and substance use disorders on outcomes in adolescents and young adults with opioid use disorder: a retrospective cohort study. Pharmaceuticals (Basel), 2025. 18(5).","DOI":"10.3390\/ph18050609"},{"key":"7916_CR4","doi-asserted-by":"publisher","first-page":"108996","DOI":"10.1016\/j.drugalcdep.2021.108996","volume":"228","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, et al. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug Alcohol Depend. 2021;228:108996.","journal-title":"Drug Alcohol Depend"},{"key":"7916_CR5","doi-asserted-by":"publisher","first-page":"109551","DOI":"10.1016\/j.drugalcdep.2022.109551","volume":"238","author":"T Santo","year":"2022","unstructured":"Santo T, et al. Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. Drug Alcohol Depend. 2022;238:109551.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"7916_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13722-024-00467-5","volume":"19","author":"G Rolov\u00e1","year":"2024","unstructured":"Rolov\u00e1 G, et al. Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway. Addict Sci Clin Pract. 2024;19(1):37.","journal-title":"Addict Sci Clin Pract"},{"key":"7916_CR7","doi-asserted-by":"crossref","unstructured":"Chen Y et al. Opioid Use Disorder and nonfatal opioid-involved overdose among medicaid-enrolled US Youth, 2020\u20132023. JAMA Pediatr. 2025.","DOI":"10.1001\/jamapediatrics.2025.4105"},{"issue":"10","key":"7916_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaac.2020.05.005","volume":"59","author":"HJ Walter","year":"2020","unstructured":"Walter HJ, et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. J Am Acad Child Adolesc Psychiatry. 2020;59(10):1107\u201324.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"7916_CR9","doi-asserted-by":"crossref","unstructured":"Cheung AH et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management. Pediatrics. 2018;141(3).","DOI":"10.1542\/peds.2017-4082"},{"key":"7916_CR10","doi-asserted-by":"crossref","unstructured":"Peterson BS et al. Treatments for ADHD in Children and Adolescents: A Systematic Review. Pediatrics. 2024;153(4).","DOI":"10.1542\/peds.2024-065787"},{"key":"7916_CR11","doi-asserted-by":"crossref","unstructured":"Wolraich ML et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit\/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4).","DOI":"10.1542\/peds.2019-2528"},{"issue":"1","key":"7916_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/01.chi.0000242240.69678.c4","volume":"46","author":"J McClellan","year":"2007","unstructured":"McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107\u201325.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"7916_CR13","unstructured":"Substance Use Disorder treatment for people with co-occurring disorders: updated 2020 [Internet]. Rockville (MD): Substance abuse and mental health services administration (US); 2020. (Treatment Improvement Protocol (TIP) Series, No. 42.) Chap. 7\u2014Treatment models and settings for people with co-occurring Disorders. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK571024\/"},{"issue":"3\u20134","key":"7916_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/19371918.2013.774673","volume":"28","author":"TM Kelly","year":"2013","unstructured":"Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health. 2013;28(3\u20134):388\u2013406.","journal-title":"Soc Work Public Health"},{"key":"7916_CR15","doi-asserted-by":"crossref","unstructured":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med, 2020. 14(2S Suppl 1): pp. 1\u201391.","DOI":"10.1097\/ADM.0000000000000633"},{"issue":"10","key":"7916_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.addbeh.2009.03.008","volume":"34","author":"JR Cornelius","year":"2009","unstructured":"Cornelius JR, et al. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav. 2009;34(10):905\u20139.","journal-title":"Addict Behav"},{"issue":"1","key":"7916_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/add.12698","volume":"110","author":"X Zhou","year":"2015","unstructured":"Zhou X, et al. Efficacy and tolerability of antidepressants in the treatment of adolescents and young adults with depression and substance use disorders: a systematic review and meta-analysis. Addiction. 2015;110(1):38\u201348.","journal-title":"Addiction"},{"issue":"2","key":"7916_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamapediatrics.2013.431","volume":"167","author":"KR Merikangas","year":"2013","unstructured":"Merikangas KR, et al. Medication Use in US Youth With Mental Disorders. JAMA Pediatr. 2013;167(2):141\u20138.","journal-title":"JAMA Pediatr"},{"issue":"4","key":"7916_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jaac.2012.12.006","volume":"52","author":"M Olfson","year":"2013","unstructured":"Olfson M, He JP, Merikangas KR. Psychotropic medication treatment of adolescents: results from the National Comorbidity Survey-Adolescent Supplement. J Am Acad Child Adolesc Psychiatry. 2013;52(4):378\u201388.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"7916_CR20","doi-asserted-by":"crossref","unstructured":"Chua KP et al. Antidepressant Dispensing to US Adolescents and Young Adults: 2016\u20132022. Pediatrics. 2024;153(3).","DOI":"10.1542\/peds.2023-064245"},{"issue":"12","key":"7916_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.18553\/jmcp.2024.30.12.1455","volume":"30","author":"P Tran","year":"2024","unstructured":"Tran P, et al. Antidepressant therapeutic strategies and health care utilization in patients with depression. J Managed Care Specialty Pharm. 2024;30(12):1455\u201366.","journal-title":"J Managed Care Specialty Pharm"},{"key":"7916_CR22","doi-asserted-by":"crossref","unstructured":"Calarco CA, Lobo MK. Chapter Six - Depression and substance use disorders: Clinical comorbidity and shared neurobiology, in International Review of Neurobiology, E.S. Calipari and N.W. Gilpin, Editors. 2021, Academic Press. pp. 245\u2013309.","DOI":"10.1016\/bs.irn.2020.09.004"},{"issue":"3","key":"7916_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jcpp.13202","volume":"61","author":"JB Dwyer","year":"2020","unstructured":"Dwyer JB, et al. Annual Research Review: Defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry. 2020;61(3):312\u201332.","journal-title":"J Child Psychol Psychiatry"},{"issue":"5","key":"7916_CR24","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1097\/DBP.0000000000001296","volume":"45","author":"C Kazarov","year":"2024","unstructured":"Kazarov C, et al. Trends in Pediatric Attention-Deficit Hyperactive Disorder Diagnoses and Prescription Utilization: 2016 to 2019. J Dev Behav Pediatr. 2024;45(5):e397\u2013405.","journal-title":"J Dev Behav Pediatr"},{"issue":"1","key":"7916_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s12888-022-04188-4","volume":"22","author":"J Schein","year":"2022","unstructured":"Schein J, et al. Treatment patterns among children and adolescents with attention-deficit\/hyperactivity disorder in the United States \u2013 a retrospective claims analysis. BMC Psychiatry. 2022;22(1):555.","journal-title":"BMC Psychiatry"},{"issue":"9","key":"7916_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727\u201338.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"7916_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/0269881113519509","volume":"28","author":"B Bolea-Alama\u00f1ac","year":"2014","unstructured":"Bolea-Alama\u00f1ac B, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(3):179\u2013203.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"7916_CR28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","volume":"46","author":"S Pliszka","year":"2007","unstructured":"Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894\u2013921.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"7916_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/HRP.0000000000000122","volume":"25","author":"PJ Carpentier","year":"2017","unstructured":"Carpentier PJ, Levin FR. Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us? Harv Rev Psychiatry. 2017;25(2):50\u201364.","journal-title":"Harv Rev Psychiatry"},{"key":"7916_CR30","doi-asserted-by":"publisher","first-page":"e083658","DOI":"10.1136\/bmj-2024-083658","volume":"390","author":"L Zhang","year":"2025","unstructured":"Zhang L, et al. ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ. 2025;390:e083658.","journal-title":"BMJ"},{"key":"7916_CR31","doi-asserted-by":"crossref","unstructured":"Barbuti M et al. Challenges of treating ADHD with comorbid substance use disorder: considerations for the clinician. J Clin Med. 2023;12(9).","DOI":"10.3390\/jcm12093096"},{"issue":"Suppl 2","key":"7916_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2020-023523F","volume":"147","author":"AE Spencer","year":"2021","unstructured":"Spencer AE, et al. Principles of Care for Young Adults With Co-Occurring Psychiatric and Substance Use Disorders. Pediatrics. 2021;147(Suppl 2):229\u201339.","journal-title":"Pediatrics"},{"key":"7916_CR33","unstructured":"American Society of Addiction Medicine, i.b., et al., The ASAM criteria: treatment criteria for addictive, substance-related, and co-occurring conditions. Fourth edition. ed. American Society of Addiction Medicine criteria et al. 2023, Center City, Minnesota: Hazelden Publishing."},{"issue":"60, 2009","key":"7916_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.psych.60.110707.163456","volume":"60","author":"EH Hawkins","year":"2009","unstructured":"Hawkins EH. A Tale of Two Systems: Co-Occurring Mental Health and Substance Abuse Disorders Treatment for Adolescents. Ann Rev Psychol. 2009;60(60, 2009):197\u2013227.","journal-title":"Ann Rev Psychol"},{"key":"7916_CR35","doi-asserted-by":"publisher","first-page":"209296","DOI":"10.1016\/j.josat.2024.209296","volume":"160","author":"RK McHugh","year":"2024","unstructured":"McHugh RK, et al. Cognitive behavioral therapy for anxiety and opioid use disorder: Development and pilot testing. J Subst Use Addict Treat. 2024;160:209296.","journal-title":"J Subst Use Addict Treat"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-07916-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:40:56Z","timestamp":1774615256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-07916-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7916"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-07916-2","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) at Nationwide Children\u2019s Hospital (Study ID: STUDY00003322). The study was conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments. Given the retrospective nature of this study using de-identified electronic medical records, the requirement for informed consent was waived by the IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study does not contain any individual person\u2019s data in any form (including individual details, images, or videos).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}